Skip to main content
. 2015 Aug 20;10(8):e0135930. doi: 10.1371/journal.pone.0135930

Fig 2. Schematic expression of platelet activation markers CD62P, PAC-1, CD63 and CD40 L in PKU patients (group I) versus controls (group II).

Fig 2

Histobars representing a) percentage of positive platelets as [median; interquartile range]: CD62P: [2.0; 1.6–2.7] versus [2.1; 1.57–2.8], p = 0.86 and PAC-1: [0.46; 0.32–0.68] versus [0.55; 0.42–0.71], p = 0.29; b) Mean immunofluorescence intensity (MFI); [median; interquartile range]: CD63 [12.5; 11.0–14.9] versus [13.23; 11.61–15.25], p = 0.3; and CD40L [16.31; 13.10–18.7] versus [16.5; 13.5–19.3], p = 0.62.